Teva launched the first generic versions of the Truvada and Atripla tablets

Teva has launched the first generic versions of the Truvada and Atripla tablets developed by Gilead. Truvada is intended to reduce the risk of contracting AIDS during sexual intercourse in patients weighing at least 37 kg. Atripela is intended for the treatment of AIDS in patients weighing 40 kg and is a drug that includes 3 active ingredients in one pill, including the active ingredient of Truvada.
"Truvada's sales in the U.S. totaled $ 753 million in the first half of 2020, down 37% from the same period in 2019. Truvada's sales in the 12 months ended June 2020 totaled $ 2.2 billion. B totaled $ 176 million in the first half of 2020, a decrease of 31% compared to the same period in 2019, and sales of Atripela in the US in the 12 months ended June 2020 amounted to $ 422 million.